For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- Number of Contract Sales Reps Increased to 4,148 as of Oct. 2014: CSO Association
February 4, 2015
- JPWA President Reiterates Opposition to Annual NHI Price Revisions
February 2, 2015
- IMI, WADA Sign MOU to Prevent Use of Experimental Drugs for Doping
January 30, 2015
- July-Sept. Generic Share Reaches 51.3% under New Formula: JGA
January 30, 2015
- JPMA Draft Guidelines Urge Companies to Separate Ad Reviewing Bodies from Sales Units
January 27, 2015
- Chuikyo Members Divided on Usage of Savings from NHI Price Cuts
January 26, 2015
- 3-Price Bracket Rule for Generics Causing Various Distortions, Problems: JGA President
January 23, 2015
- Ihoken Proposes New Pricing Rule for Regenerative Medicines
January 22, 2015
- Some LDP Members Keen to Tackle Kampo NHI Price Problem
January 21, 2015
- JSMI to Announce in May a “Grand Design” for OTC Drug Industry
January 21, 2015
- JPMA Notifies of Unfavorable Expressions for Disease Awareness Ads
January 16, 2015
- Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading
January 15, 2015
- Wholesalers Must Revamp Biz Model to Cope with Change in Sales Mix: JPWA Chief
January 14, 2015
- Price Grouping Rule Triggered “Distortion” in Generic Market: JGA President
January 9, 2015
- Pharma Biz Leader Airs Concern over Effective Tax Hikes
January 8, 2015
- Sumitomo Dainippon President Praises Govt’s Healthcare Measures
January 6, 2015
- FPMAJ Chairman Wishes for Good Environment for Drug Innovation in 2015
January 1, 2015
- FPMAJ “Hasn’t Given Up” on Maintenance of 30% R&D Tax Deduction Cap: Chairman
December 24, 2014
- EFPIA Japan Chairman Calls for More Rewards for Innovation
December 22, 2014
- Bristol-Myers Reprimanded by JPMA over Misconduct in Sprycel Trial
December 19, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…